NCT06093308View on ClinicalTrials.gov

A Study in Elderly Chinese Subjects With Underlying Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 12, 2023

Primary Completion Date

August 25, 2023

Study Completion Date

August 25, 2023

Conditions
Elderly Subjects With Underlying Diseases
Interventions
DRUG

Deuremidevir Hydrobromide Tablets

Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Shanghai Vinnerna Biosciences Co., Ltd.

INDUSTRY